An interventional study of Abbreviated PB MRI and Gene mutation test in Pancreas Cancer, sponsored by Seoul National University Hospital. Active, not recruiting at 1 site in Korea, Republic of. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-18.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Screening
This study aims to establish a prospective cohort of developing pancreas cancer and surveillance MRI protocol. With the focused surveillance protocol, we perform surveillance for pancreas cancer for five years to estimate the risk of pancreas cancer and the clinical feasibility of the surveillance MRI.
3,236 studies on the registry are indexed under Pancreatic Neoplasms; 900 are open to participants now.
This study's enrollment of 200 is above the median of 46 across 2,425 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Short and Focused non-contrast MRI for surveillance
Diagnostic Test: Abbreviated PB MRI · Genetic: Gene mutation test · Diagnostic Test: Conventional follow-up
Annual non-contrast PB MRI.
K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
Detection of pancreas cancer
number of detected pancreas cancer (resectable \& BRPC only) in surveillance MRI.
Time frame: 1 year after the last surveillance MRI.
Scan time of abbreviated PB MRI for surveillance
table time, in-room time measurement for feasibility
Time frame: 1 month after the first surveillance MRI.
Estimation of pancreas cancer risk
rate of developing pancreas cancer during the study period
Time frame: 1 year after the last surveillance MRI.
Detection of pancreas cancer
number of detected pancreas cancer of all stages (resectable, BRPC, LAPC, metastatic) in surveillance MRI.
Time frame: 1 year after the last surveillance MRI.
Comparison of performance of abbreviated PB MRI
comparison of the rates of pancreas cancer detection between abbreviated MRI and conventional follow-up methods (in available cases)
Time frame: 1 year after the last surveillance MRI.
Identification of super-high risk group of developing pancreas cancer
Identification of any common radiologic features and gene mutation in participants in whom pancreas cancer develop during the study period.
Time frame: 1 year after the last surveillance MRI.
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital